We invite you to complete this short Consensus Survey in preparation for the MICROB-PREDICT Consensus Conference on Wednesday, 27 May 2026, during EASL Congress in Barcelona, Spain. Scope: Microbiome-based mechanisms and biomarkers for improved patient stratification and prediction of therapeutic…
22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensa…
22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensa…
MICROB-PREDICT and DECISION are inviting the liver community to attend their half-day online symposium, Management of Acute-on-chronic Liver Failure, on 2 September 2021. This event is timed to precede EASL’s School of Hepatology, taking place 3–4 September, in Frankfurt, Germany, addressing the …
Five EU-funded projects to explore at ILC 2021 15 June 2021 EASL is proud to be the communications and dissemination arm for five major EU-funded projects for diagnosing and combating liver disease: A-TANGO, DECISION, LITMUS, Liver-Screen, and MICROB-PREDICT. We spread the news about their devel…
Researchers from EF Clif identify the causes that precipitate the onset of the most serious stage of cirrhosis: the syndrome of Acute-On-Chronic Liver Failure (ACLF). Barcelona, December 9, 2020 – A new investigation of the PREDICT study, which was led and coordinated from Barcelona by Prof. Jone…
Researchers at EF Clif identify three different clinical courses for the first time, in patients with acute decompensated cirrhosis without acute-on-chronic liver failure (ACLF). July 14, 2020 – A clinical study led by the European Foundation for the Study of Chronic Liver Failure (EF Clif) in Ba…
According to a study conducted by the EF-Clif published in Gastroenterology This study has shown for the first time that the administration of albumin at high doses has an immunomodulatory effect both in the short (INFECIR-2) and long-term (Pilot-PRECIOSA) in patients with decompensated cirrhosis…
SCIENTIFIC PRESS RELEASE Developing personalised targets for treatment of decompensated cirrhosis and acute-on-chronic liver failure (ACLF) Barcelona, Spain – An EU Horizon 2020-financed project investigating methods to better understand the role of the microbiome to help stratify patient health …
